Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
AIM: Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), and progresses to the end stage of liver disease. Biochemical markers of liver fibrosis are strongly associated with the degree of histological liver fibrosis in patients with chronic liver disease. However, data are few on the usefulness of markers in NAFLD patients. The aim of this study was to identify better noninvasive predictors of hepatic fibrosis, with special focus on markers of liver fibrosis, type VI collagen 7S domain and hyaluronic acid. METHODS: One hundred and twelve patients with histologically proven NAFLD were studied. RESULTS: The histological stage of NAFLD correlated with several clinical and biochemical variables, the extent of hepatic fibrosis and the markers of liver fibrosis were relatively strong associated. The best cutoff values to detect NASH were assessed by using receiver operating characteristic analysis: type VI collagen 7S domain > or =5.0 ng/mL, hyaluronic acid > or =43 ng/mL. Both markers had a high positive predictive value: type VI collagen 7S domain, 86% and hyaluronic acid, 92%. Diagnostic accuracies of these markers were evaluated to detect severe fibrosis. Both markers showed high negative predictive values: type VI collagen 7S domain (> or =5.0 ng/mL), 84% and hyaluronic acid (> or =50 ng/mL), 78%, and were significantly and independently associated with the presence of NASH or severe fibrosis by logistic regression analysis. CONCLUSION: Both markers of liver fibrosis are useful in discriminating NASH from fatty liver alone or patients with severe fibrosis from patients with non-severe fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“NAFLD patients with severe fibrosis have a poor prognosis [ 18 ].”
BackgroundLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Non‐alcoholic steatohepatitis (NASH): where are we now and where are we going?
Day, C. P. (2002) · Gut · doi:10.1136/gut.50.5.585 · Cited by 181
Cited by
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
The good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509
Ratziu, V., Massard, J., Charlotte, F., Messous, D., Imbert-Bismut, F., Bonyhay, L., Tahiri, M., Munteanu, M., Thabut, D., Cadranel, J. F., et al. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-6 · Cited by 492
Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome
Roulot, D., Czernichow, S., Le Clésiau, H., Costes, J.-L., Vergnaud, A.-C., & Beaugrand, M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.020 · Cited by 439
Chen, J., Talwalkar, J. A., Yin, M., Glaser, K. J., Sanderson, S. O., & Ehman, R. L. (2011) · Radiology · doi:10.1148/radiol.11101942 · Cited by 432
Yoneda, M., Yoneda, M., Mawatari, H., Fujita, K., Endo, H., Iida, H., Nozaki, Y., Yonemitsu, K., Higurashi, T., Takahashi, H., et al. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.019 · Cited by 428
Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal
Machado, M. V., & Cortez-Pinto, H. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.021 · Cited by 412
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
the LIDO Study Group and the CYTOL study group, Poynard, T., Ratziu, V., Charlotte, F., Messous, D., Munteanu, M., Imbert-Bismut, F., Massard, J., Bonyhay, L., Tahiri, M., et al. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-34 · Cited by 302
Nonalcoholic Fatty Liver Disease in Severely Obese Subjects
Gholam, P. M., Flancbaum, L., Machan, J. T., Charney, D. A., & Kotler, D. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01041.x · Cited by 296
Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers
Twigg, S. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1991 · Cited by 286
Noninvasive evaluation of NAFLD
Castera, L., Vilgrain, V., & Angulo, P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.175 · Cited by 273
Mak, K. M., & Mei, R. (2017) · The Anatomical Record · doi:10.1002/ar.23567 · Cited by 269
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy
Sebastiani, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3682 · Cited by 266
ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population
Wang, J., Xu, C., Xun, Y., Lu, Z., Shi, J., Yu, C., & Li, Y. (2015) · Scientific Reports · doi:10.1038/srep16494 · Cited by 173
Nonalcoholic fatty liver disease: Diagnostic biomarkers
Hadizadeh, F., Faghihimani, E., & Adibi, P. (2017) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v8.i2.11 · Cited by 168
LESMANA, C. R. A., HASAN, I., BUDIHUSODO, U., GANI, R. A., KRISNUHONI, E., AKBAR, N., & LESMANA, L. A. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00386.x · Cited by 76
Maleki, I. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i35.12566 · Cited by 22
Metadata
- Authors
- Sakugawa, H.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2005
- Volume
- 11
- Issue
- 2
- Pages
- 255
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2025946383
- Cited by
- 156
- References
- 7
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.